NeoGenomics (NeoGenomics) Retained Earnings : $-274.1 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is NeoGenomics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. NeoGenomics's retained earnings for the quarter that ended in Mar. 2024 was $-274.1 Mil.

NeoGenomics's quarterly retained earnings declined from Sep. 2023 ($-232.7 Mil) to Dec. 2023 ($-247.1 Mil) and declined from Dec. 2023 ($-247.1 Mil) to Mar. 2024 ($-274.1 Mil).

NeoGenomics's annual retained earnings declined from Dec. 2021 ($-14.8 Mil) to Dec. 2022 ($-159.1 Mil) and declined from Dec. 2022 ($-159.1 Mil) to Dec. 2023 ($-247.1 Mil).

NeoGenomics Retained Earnings Historical Data

The historical data trend for NeoGenomics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Retained Earnings Chart

NeoGenomics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-11.36

-7.19

-14.84

-159.09

-247.06

NeoGenomics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial															-189.88	-214.21	-232.73	-247.06	-274.12

NeoGenomics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

NeoGenomics (NAS:NEO) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

NeoGenomics (NeoGenomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » Retained Earnings

Comparable Companies

VCYT MYGN TWST OPK LAB CDNA NEOG CSTL FLGT GH TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN

Traded in Other Exchanges

NG9:Germany

Address

9490 NeoGenomics Way, Fort Myers, FL, USA, 33912

Website

https://www.neogenomics.com

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.

Executives

Alicia C Olivo	officer: General Counsel	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Anthony P. Zook	director	C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Elizabeth Floegel	director	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Neil Gunn	director	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan	officer: Chief Accounting Officer	HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Jeffrey Scott Sherman	officer: Chief Financial Officer	103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Melody Harris	officer: President, Enterprise Ops	4801 WEST BYRON PLACE, DENVER CO 80211
Warren Stone	officer: President, Clinical Services	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Brian Perez	director	12100 6TH AVENUE, LAKEWOOD CO 80228
Christopher M Smith	officer: Chief Executive Officer	125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni	officer: President of Lab Operations	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri	officer: President and CCO, Inivata	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Sholehvar	officer: President, Clinical Services	9490 NEOGENOMICS WAY, FORT MYERS FL 33912
William Bonello	officer: VP, Investor Relations	12780 WESTLINKS DRIVE, FORT MYERS FL 33913
Kathryn B Mckenzie	officer: Principal Accounting Officer	12780 WESTLINKS DRIVE, FORT MYERS FL 33913